

Financial news for IMMU dated on 2020-06-08: Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.

Financial news for IMMU dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimune Pops On Insider Buying, Immuteq Gets R&D Grant

Financial news for IMMU dated on 2020-05-28: The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetrphase Receives Sweetened Offer

Financial news for IMMU dated on 2020-05-27: Immunomedics Announces Its CEO And President Will Step Down

Financial news for IMMU dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for IMMU dated on 2020-05-26: Stocks That Hit 52-Week Highs On Tuesday

Financial news for IMMU dated on 2020-05-24: The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Financial news for IMMU dated on 2020-05-21: The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Financial news for IMMU dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for IMMU dated on 2020-05-18: Stocks That Hit 52-Week Highs On Monday

Financial news for IMMU dated on 2020-05-15: Stocks That Hit 52-Week Highs On Friday

Financial news for IMMU dated on 2020-05-13: Immunomedics Will Present New Trodelvy Data In Non-Breast Cancer Indications At ASCO

Financial news for IMMU dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for IMMU dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for IMMU dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for IMMU dated on 2020-05-08: The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda

Financial news for IMMU dated on 2020-05-07: H.C. Wainwright Maintains Buy on Immunomedics, Lowers Price Target to \$54

Financial news for IMMU dated on 2020-05-07: Morgan Stanley Maintains Equal-Weight on Immunomedics, Raises Price Target to \$32

Financial news for IMMU dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for IMMU dated on 2020-05-06: Immunomedics Q3 EPS \$(0.440) Beats \$(0.450) Estimate

Financial news for IMMU dated on 2020-05-06: Stocks That Hit 52-Week Highs On Wednesday

Financial news for IMMU dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for IMMU dated on 2020-05-05: Why Immunomedics Is Trading Higher Today

Financial news for IMMU dated on 2020-05-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for IMMU dated on 2020-05-05: Benzinga's Top Upgrades, Downgrades For May 5, 2020

Financial news for IMMU dated on 2020-05-05: Immunomedics shares are trading higher after Barclays initiated coverage on the company's stock with an Overweight rating and \$40 price target.

Financial news for IMMU dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for IMMU dated on 2020-05-05: Barclays Initiates Coverage On Immunomedics with Overweight Rating, Announces Price Target to \$40

Financial news for IMMU dated on 2020-05-04: Immunomedics Reports Commercial Availability Of TRODELVY In US

Financial news for IMMU dated on 2020-05-03: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates

Financial news for IMMU dated on 2020-05-02: Notable Insider Buys This Past Week: Immunomedics, Simply Good Foods And More

Financial news for IMMU dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for IMMU dated on 2020-04-29: Stocks That Hit 52-Week Highs On Wednesday

Financial news for IMMU dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for IMMU dated on 2020-04-28: Immunomedics shares are trading lower after the company announced a proposed public offering of \$350 million worth of its common stock.

Financial news for IMMU dated on 2020-04-27: 13 Stocks Moving In Monday's After-Hours Session

Financial news for IMMU dated on 2020-04-27: Immunomedics shares are trading lower after the company announced a proposed public offering of \$350 million worth of its common stock.

Financial news for IMMU dated on 2020-04-27: Immunomedics Announces A Proposed Public Offering Of \$350 Million Worth Of Its Common Stock. No Size Disclosed

Financial news for IMMU dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for IMMU dated on 2020-04-24: Benzinga's Top Upgrades, Downgrades For April 24, 2020

Financial news for IMMU dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for IMMU dated on 2020-04-24: 10 Biggest Price Target Changes For Friday

Financial news for IMMU dated on 2020-04-24: Goldman Sachs Upgrades Immunomedics to Neutral, Raises Price Target to \$22

Financial news for IMMU dated on 2020-04-24: 76 Biggest Movers From Yesterday

Financial news for IMMU dated on 2020-04-23: Mid-Afternoon Market Update: Sleep Number Surges On Strong Q1 Results; NETGEAR Shares Drop

Financial news for IMMU dated on 2020-04-23: P/E Ratio Insights for Immunomedics

Financial news for IMMU dated on 2020-04-23: 54 Stocks Moving In Thursday's Mid-Day Session

Financial news for IMMU dated on 2020-04-23: Mid-Day Market Update: Crude Oil Jumps 31%; Invesco Shares Slide On Downbeat Earnings

Financial news for IMMU dated on 2020-04-23: Guggenheim Maintains Buy on Immunomedics, Raises Price Target to \$39

Financial news for IMMU dated on 2020-04-23: Stocks That Hit 52-Week Highs On Thursday

Financial news for IMMU dated on 2020-04-23: Mid-Morning Market Update: Markets Open Higher; Eli Lilly Beats Q1 Views

Financial news for IMMU dated on 2020-04-23: Immunomedics shares are trading higher

after the FDA granted accelerated approval for the company's Trodelvy in previously-treated metastatic triple-negative breast cancer.

Financial news for IMMU dated on 2020-04-23: Piper Sandler Maintains Overweight on Immunomedics, Raises Price Target to \$40

Financial news for IMMU dated on 2020-04-23: 10 Biggest Price Target Changes For Thursday

Financial news for IMMU dated on 2020-04-23: Wells Fargo Maintains Overweight on Immunomedics, Raises Price Target to \$41

Financial news for IMMU dated on 2020-04-23: The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt

Financial news for IMMU dated on 2020-04-23: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for IMMU dated on 2020-04-23: 38 Stocks Moving in Thursday's Pre-Market Session

Financial news for IMMU dated on 2020-04-23: H.C. Wainwright Maintains Buy on Immunomedics, Raises Price Target to \$60

Financial news for IMMU dated on 2020-04-22: FDA Grants Accelerated Approval for Immunomedics' Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer

Financial news for IMMU dated on 2020-04-22: Immunomedics Shares Unaffected As Traders Circulate Apr. 22-Dated FDA.gov Accessdata Site Showing Approval For Co.'s Trodelvy

Financial news for IMMU dated on 2020-04-22: Stocks That Hit 52-Week Highs On Wednesday

Financial news for IMMU dated on 2020-04-15: Morgan Stanley Maintains Equal-Weight on Immunomedics, Raises Price Target to \$22

Financial news for IMMU dated on 2020-04-09: Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further \$2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race.

Financial news for IMMU dated on 2020-04-07: Immunomedics shares are trading higher after the company was granted FDA fast track designation for its Sacituzumab Govitecan for the treatment of adult patients with locally advanced, and metastatic urothelial cancer.

Financial news for IMMU dated on 2020-04-07: Immunomedics Reports FDA Granted Fast Track Designation For Sacituzumab Govitecan For Treatment Of Adult Patients With Locally Advanced, Metastatic Urothelial Cancer

Financial news for IMMU dated on 2020-04-07: H.C. Wainwright Maintains Buy on Immunomedics, Raises Price Target to \$34

Financial news for IMMU dated on 2020-04-07: 84 Biggest Movers From Yesterday

Financial news for IMMU dated on 2020-04-06: Mid-Afternoon Market Update: Dow Surges Over 1200 Points; Millendo Therapeutics Shares Plummet

Financial news for IMMU dated on 2020-04-06: 66 Stocks Moving In Monday's Mid-Day Session

Financial news for IMMU dated on 2020-04-06: Mid-Day Market Update: Crude Oil Down Over 6%; Wayfair Shares Spike Higher

Financial news for IMMU dated on 2020-04-06: Mid-Morning Market Update: Markets Open Higher; Simply Good Foods Beats Q2 Estimates

Financial news for IMMU dated on 2020-04-06: Immunomedics Shares Roar Higher On 'Remarkable Results' For Drug Candidate

Financial news for IMMU dated on 2020-04-06: Immunomedics Shares Up 96% Following News Co. Stopped ASCENT Trial Early Due To Overwhelming Efficacy; Jefferies Sees Event As De-Risking Given SG Is Now Well Positioned To Get Accelerated Approval

Financial news for IMMU dated on 2020-04-06: Immunomedics shares are trading higher after the company said it would stop its Ascent Study due to compelling evidence of efficacy.

Financial news for IMMU dated on 2020-04-06: Immunomedics Shares Resume Trade, Up 155%

Financial news for IMMU dated on 2020-04-06: Immunomedics Announces Ascent Study To Be Stopped For Compelling Evidence Of Efficacy

Financial news for IMMU dated on 2020-04-06: Immunomedics Inc Appointed Harout Semerjian As President And Chief Executive Officer And As A Member Of Board, Effective April 16, 2020

Financial news for IMMU dated on 2020-04-06: Immunomedics Announces Harout Semerjian CEO

Financial news for IMMU dated on 2020-04-06: 74 Biggest Movers From Friday

Financial news for IMMU dated on 2020-04-03: Immunomedics Spokesperson Says Expecting To Address FDA Observations In Coming Weeks, Doesn't See Need For More Inspections

Financial news for IMMU dated on 2020-04-03: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for IMMU dated on 2020-04-03: Immunomedics Could Face Second FDA Rejection For Breast Cancer Drug, Goldman Sachs Says In Double Downgrade

Financial news for IMMU dated on 2020-04-03: Benzinga's Top Upgrades, Downgrades For April 3, 2020

Financial news for IMMU dated on 2020-04-03: Immunomedics shares are trading lower after Goldman Sachs downgraded the company's stock from Buy to Sell and announced a \$5 price target.

Financial news for IMMU dated on 2020-04-03: 25 Stocks Moving in Friday's Pre-Market Session

Financial news for IMMU dated on 2020-04-03: Goldman Sachs Downgrades Immunomedics to Sell, Announces \$5 Price Target

Financial news for IMMU dated on 2020-04-02: Immunomedics Shares Unaffected Following Circulation Of Dept. Of Health & Human Services Doc From FDA Related To Inspection Of Silver Spring, Maryland Facility

Financial news for IMMU dated on 2020-04-02: 72 Biggest Movers From Yesterday

Financial news for IMMU dated on 2020-04-01: Cowen Says Spoke With Immunomedics Mgmt, Mgmt Remains Confident In Sacituzumab Approval; Firm Says Expects Drug To 'become standard of care in TNBC'

Financial news for IMMU dated on 2020-04-01: 54 Stocks Moving In Wednesday's Mid-Day Session

Financial news for IMMU dated on 2020-04-01: Mid-Day Market Update: ProPetro Slides After Q4 Results; InflaRx Shares Jump

Financial news for IMMU dated on 2020-04-01: Mid-Morning Market Update: Markets Open Lower; UniFirstTops Q2 Estimates

Financial news for IMMU dated on 2020-04-01: Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.

Financial news for IMMU dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for IMMU dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for IMMU dated on 2020-03-03: Morgan Stanley Maintains Equal-Weight on Immunomedics, Raises Price Target to \$19

Financial news for IMMU dated on 2020-02-27: Immunomedics Q2 EPS \$(0.5) Misses \$(0.46) Estimate, Sales \$300K Miss \$530K Estimate

Financial news for IMMU dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lilly, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for IMMU dated on 2020-02-25: Shares of several healthcare companies are trading lower as markets fall amid the continued spread of the coronavirus, which

has raised concerns of a global economic slowdown, impacting stocks across sectors.

Financial news for IMMU dated on 2020-02-25: Immunomedics shares are trading higher in sympathy with the overall market on a rebound following Monday's steep selloff.

Financial news for IMMU dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for IMMU dated on 2020-01-20: 7 Blockbuster Drugs Expected To Be Launched In 2020

Financial news for IMMU dated on 2019-12-27: 5 Biggest Price Target Changes For Friday

Financial news for IMMU dated on 2019-12-27: The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

Financial news for IMMU dated on 2019-12-27: HC Wainwright & Co. Maintains Buy on Immunomedics, Raises Price Target to \$31

Financial news for IMMU dated on 2019-12-27: 60 Biggest Movers From Yesterday

Financial news for IMMU dated on 2019-12-26: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for IMMU dated on 2019-12-26: Immunomedics shares are trading higher after the company announced the FDA accepted for filing the company's BLA seeking accelerated approval of sacituzumab govitecan to treat metastatic triple-negative breast cancer.

Financial news for IMMU dated on 2019-12-26: Immunomedics Reports FDA Acceptance Of Filing Of Biologics License Application Resubmission For Sacrituzumab Govitecan To Treat Metastatic Triple-Negative Breast Cancer

Financial news for IMMU dated on 2019-12-20: UPDATE: Bank Of America On Immunomedics Notes Co's ADC Sacituzumab Govitecan In Triple Negative Breast Cancer 'showed a 33% overall response rate (ORR) in third-line in ph 2 study, which we view positively' Has Potential To Disrupt Current Paradigm

Financial news for IMMU dated on 2019-12-20: UPDATE: Bank Of America Initiates Immunomedics With Buy, \$26 Target Notes Co's 'Novel ADC platform tackling cancers of high undermet need'

Financial news for IMMU dated on 2019-12-20: Bank of America Initiates Coverage On Immunomedics with Buy Rating, Announces \$26 Price Target

Financial news for IMMU dated on 2019-12-12: The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

Financial news for IMMU dated on 2019-12-11: Stocks That Hit 52-Week Highs On Wednesday

Financial news for IMMU dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for IMMU dated on 2019-12-10: Stocks That Hit 52-Week Highs On Tuesday

Financial news for IMMU dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for IMMU dated on 2019-12-09: Immunomedics Announces The Closing Of The Public Offering Of Common Stock

Financial news for IMMU dated on 2019-12-09: 74 Biggest Movers From Friday

Financial news for IMMU dated on 2019-12-06: Immunomedics shares are trading higher in sympathy with the overall market after the U.S. added 266,000 jobs in November, beating expectations and lowering the unemployment rate to 3.5%.

Financial news for IMMU dated on 2019-12-05: 72 Biggest Movers From Yesterday

Financial news for IMMU dated on 2019-12-04: Mid-Afternoon Market Update: Dow Rises Over 200 Points; Barnes & Noble Education Shares Slide

Financial news for IMMU dated on 2019-12-04: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for IMMU dated on 2019-12-04: Immunomedics shares are trading lower after the company announced a proposed offering of \$250 million of common stock.

Financial news for IMMU dated on 2019-12-04: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for IMMU dated on 2019-12-04: The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for IMMU dated on 2019-12-03: Immunomedics shares are trading lower after the company announced a proposed offering of \$250 million of common stock.

Financial news for IMMU dated on 2019-12-03: Immunomedics Announces Proposed Public Offering Of \$250M Of Common Stock

Financial news for IMMU dated on 2019-12-03: Immunomedics Resubmits Biologics License Application To FDA For Sacituzumab Govitecan

Financial news for IMMU dated on 2019-11-26: Immunomedics Option Alert: Jan 17 \$19 Calls Sweep (2) above Ask!: 1000 @ \$1.775 vs 5155 OI; Ref=\$18.87

Financial news for IMMU dated on 2019-11-24: The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Arrowhead Earnings And More

Financial news for IMMU dated on 2019-11-19: Immunomedics shares are trading lower. Not currently seeing any company-specific news.

Financial news for IMMU dated on 2019-11-01: Immunomedics shares are trading higher in sympathy with the overall market on better-than-expected October jobs growth and optimism around the U.S.-China trade deal.

Financial news for IMMU dated on 2019-10-30: Immunomedics Q1 EPS \$(0.49) Down From \$(0.34) YoY

Financial news for IMMU dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for IMMU dated on 2019-10-23: Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

Financial news for IMMU dated on 2019-10-17: 54 Biggest Movers From Yesterday

Financial news for IMMU dated on 2019-10-16: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for IMMU dated on 2019-10-16: Immunomedics shares are trading higher despite no company-specific news. The could potentially be a rebound after the stock dropped approximately 13% over the past month.

Financial news for IMMU dated on 2019-10-06: Notable Insider Buys In The Past Week: Immunomedics, Tenet Healthcare, Ulta Beauty

Financial news for IMMU dated on 2019-10-03: 28 Stocks Moving In Thursday's Mid-Day Session

Financial news for IMMU dated on 2019-10-03: Immunomedics shares are trading higher on continued momentum after the company announced a research collaboration with the US Department of Defense to develop a new therapeutic against campylobacter.

Financial news for IMMU dated on 2019-10-02: Immunomedics shares are trading higher after the company announced a research collaboration with the US Department of Defense to develop a new therapeutic against campylobacter.

Financial news for IMMU dated on 2019-10-02: Immuron Announces Research Collaboration With US Department Of Defense To Develop And Clinically Evaluate New Therapeutic Against Campylobacter

Financial news for IMMU dated on 2019-10-01: Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.

Financial news for IMMU dated on 2019-10-01: 58 Biggest Movers From Yesterday

Financial news for IMMU dated on 2019-09-30: Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More

Financial news for IMMU dated on 2019-09-30: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for IMMU dated on 2019-09-30: A Look At Benzinga Pro's Most-Searched

Tickers For September 30, 2019

Financial news for IMMU dated on 2019-09-30: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, September 30, 2019

Financial news for IMMU dated on 2019-09-30: 18 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for IMMU dated on 2019-09-30: 24 Stocks Moving in Monday's Pre-Market Session

Financial news for IMMU dated on 2019-09-30: Immunomedics shares are trading lower after interim data from the company's phase 2 study of Sacituzumab Govitecan showed a 29% response rate.

Financial news for IMMU dated on 2019-09-30: Wells Fargo Maintains Market Perform on Immunomedics, Raises Price Target to \$16

Financial news for IMMU dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for IMMU dated on 2019-09-26: Immunomedics shares are trading lower despite no company-specific news. The stock has dropped approximately 16% in the past 5 days.

Financial news for IMMU dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for IMMU dated on 2019-09-24: Immunomedics shares are trading lower, not seeing any company-specific news to justify price action.

Financial news for IMMU dated on 2019-09-22: The Week Ahead In Biotech: Spotlight On ESMO Conference

Financial news for IMMU dated on 2019-09-13: Immunomedics shares are trading higher. This could potentially be continued momentum as the stock has rallied 26% over the past 5 days.

Financial news for IMMU dated on 2019-09-11: Immunomedics shares are trading higher in sympathy with healthcare stocks. Not seeing any company-specific news to justify move.

Financial news for IMMU dated on 2019-09-11: 80 Biggest Movers From Yesterday

Financial news for IMMU dated on 2019-09-10: CORRECTION: Jefferies Earlier Made Negative Comments On Data From Immunomedics Competitor, Daiichi; Initial headline incorrectly suggested the negative comments were on Immunomedics

Financial news for IMMU dated on 2019-09-10: Immunomedics shares trading higher following data out of competitor in non-small cell lung cancer space, Daiichi. A Piper Jaffray analyst said while efficacy of Daiichi's candidate was impressive, there were some safety signals popping up.

Financial news for IMMU dated on 2019-09-10: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for IMMU dated on 2019-09-10: Immunomedics Shares Higher; Jefferies Made Negative Comments On Competitor Data In Non-Small Cell Lung Cancer Space From Daiichi

Financial news for IMMU dated on 2019-09-04: Immunomedics Highlights Oral Presentation Of Sactuzumab Govitecan In Metastatic Urothelial Cancer At ESMO

Financial news for IMMU dated on 2019-08-20: Benzinga's Top Upgrades, Downgrades For August 20, 2019

Financial news for IMMU dated on 2019-08-20: Cantor Fitzgerald Initiates Coverage On Immunomedics with Overweight Rating, Announces \$28 Price Target

Financial news for IMMU dated on 2019-08-07: 42 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for IMMU dated on 2019-08-07: Immunomedics Q4 EPS \$(0.4) Up From \$(0.68) YoY

Financial news for IMMU dated on 2019-07-10: The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For

ViiV

Financial news for IMMU dated on 2019-06-30: Notable Insider Buys This Past Week: AbbVie, MGM and More

Financial news for IMMU dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for IMMU dated on 2019-06-09: Notable Insider Buys This Past Week: American Airlines, MGM and More

Financial news for IMMU dated on 2019-06-07: Immunomedics Shares Tick Higher, Now At Session High Up 4%, Following 2.4M Share Black Trade At \$12.70/Share

Financial news for IMMU dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for IMMU dated on 2019-05-09: Immunomedics Q3 EPS \$(0.46) Misses \$(0.36) Estimate, Sales \$500K Up From \$482.226K YoY

Financial news for IMMU dated on 2019-04-30: 42 Biggest Movers From Yesterday

Financial news for IMMU dated on 2019-04-29: 38 Stocks Moving In Monday's Mid-Day Session

Financial news for IMMU dated on 2019-04-29: Immunomedics shares are trading lower after the company announced the departure of their Chief Medical Officer, who is pursuing a career closer to his home in Pennsylvania.

Financial news for IMMU dated on 2019-04-29: Immunomedics to License Sacituzumab Govitecan in Asia to Everest Medicines, Immunomedics to Receive \$65M Upfront

Financial news for IMMU dated on 2019-04-08: Immunomedics Reports Promotion Deal In Which Co. Will Provide Detailing Services To J&J's Janssen For Erdafitinib In US

Financial news for IMMU dated on 2019-04-01: Immunomedics shares are trading lower after the company entered into a sales agreement with Cowen and Company to issue and sell up to \$150,000,000 worth of the company's common stock from time to time during the term of the agreement.

Financial news for IMMU dated on 2019-03-25: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for IMMU dated on 2019-03-04: Benzinga's Top Upgrades, Downgrades For March 4, 2019

Financial news for IMMU dated on 2019-03-04: H.C. Wainwright Initiates Coverage On Immunomedics with Buy Rating, Announces \$28 Price Target

Financial news for IMMU dated on 2019-02-26: Immunomedics shares have rebounded from pre-market weakness, now trading higher.

Financial news for IMMU dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for IMMU dated on 2019-02-25: Immunomedics Reports 6-Month Period Ended Dec. 31, 2018 EPS \$(0.84) vs \$(0.88) In Same Period Last Year

Financial news for IMMU dated on 2019-02-20: Immunomedics Highlights Publication Of Updated Data From Phase 2 Study Of Sacituzumab Govitecan In Patients With Metastatic Triple-Negative Breast Cancer On NEJM.org; Showed Overall Response rate 33.3%, Median Duration Of Response 7.7 Months

Financial news for IMMU dated on 2019-02-15: The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal

Financial news for IMMU dated on 2019-01-25: 21 Stocks Moving In Friday's Pre-Market Session

Financial news for IMMU dated on 2019-01-22: Morgan Stanley Downgrades Immunomedics to Equal-Weight, Lowers Price Target to \$17

Financial news for IMMU dated on 2019-01-22: 52 Biggest Movers From Friday

Financial news for IMMU dated on 2019-01-18: Mid-Afternoon Market Update: Dow Climbs Over 300 Points; Nautilus Shares Slide On Weak Guidance

Financial news for IMMU dated on 2019-01-18: Immunomedics Shares Crash As Breast

Cancer Drug Fails To Obtain Regulatory Nod

Financial news for IMMU dated on 2019-01-18: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for IMMU dated on 2019-01-18: Mid-Day Market Update: Crude Oil Up 2.8%; Tyme Technologies Shares Plummet

Financial news for IMMU dated on 2019-01-18: Mid-Morning Market Update: Markets Open Higher; Tesla Cuts 7% Of Workforce

Financial news for IMMU dated on 2019-01-18: Immunomedics shares are trading down after the company received a CRL from the FDA for its Sacituzumab Govitecan Biologics License Application.

Financial news for IMMU dated on 2019-01-18: UPDATE: Wells Fargo Downgrades Immunomedics 'following yesterday's (1/17) complete response letter (CRL) from FDA for the sacituzumab govitecan BLA In triple negative breast cancer'

Financial news for IMMU dated on 2019-01-18: Wells Fargo Downgrades Immunomedics to Market Perform, Lowers Price Target to \$18

Financial news for IMMU dated on 2019-01-18: The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug

Financial news for IMMU dated on 2019-01-18: Immunomedics Receives CRL From FDA for Sacituzumab Govitecan Biologics License Application

Financial news for IMMU dated on 2019-01-16: UPDATE: Immunomedics Filing Shows Final Award Denied Goldenberg's Claim He Was Entitled To \$1.5M Award

Financial news for IMMU dated on 2019-01-16: Immunomedics 8-K Shows Co. Received Arbitrator's Findings Of Fact, Conclusions Of Law, Final Award In Matter With David Goldenberg

Financial news for IMMU dated on 2019-01-13: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for IMMU dated on 2018-12-31: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for IMMU dated on 2018-12-28: Immunomedics 8-K Shows Co. Entered Deal With BSP Pharma To 'negotiate in good faith to execute, deliver a definitive agreement for the commercial supply by BSP to the Co. of the Co.'s sacituzumab govitecan'

Financial news for IMMU dated on 2018-12-27: 54 Biggest Movers From Yesterday

Financial news for IMMU dated on 2018-12-26: Mid-Afternoon Market Update: Dow Up Over 600 Points; Immunomedics Shares Surge

Financial news for IMMU dated on 2018-12-26: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for IMMU dated on 2018-12-26: Immunomedics shares are trading higher after the company and Johnson Matthey announced the companies have expanded their long-term master supply agreement under which Johnson Matthey will continue to scale the manufacturing of Immunomedics' CL2A-SN-38.

Financial news for IMMU dated on 2018-12-26: Immunomedics And Johnson Matthey Announce Strategic Manufacturing Partnership

Financial news for IMMU dated on 2018-12-24: 60 Biggest Movers From Friday

Financial news for IMMU dated on 2018-12-21: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for IMMU dated on 2018-12-21: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for IMMU dated on 2018-12-21: 60 Biggest Movers From Yesterday

Financial news for IMMU dated on 2018-12-20: 46 Stocks Moving In Thursday's Mid-Day Session

Financial news for IMMU dated on 2018-12-20: Immunomedics shares are trading lower following reports of a data integrity breach.

Financial news for IMMU dated on 2018-12-20: Immunomedics Shares Down 23% On Report

Of Data Integrity Breach; Hearing Morgan Stanley Has Defended Co./Stock, Suggesting Co. Mgmt. Has Said Issues Were Discovered In Late 2017, 2018

Financial news for IMMU dated on 2018-12-20: 'FDA Hits Immunomedics for Data Integrity Breach' -FDA News Reported Earlier This Week

Financial news for IMMU dated on 2018-12-20: Hearing Of A Bearish Report From Favus Institutional Research On Immunomedics

Financial news for IMMU dated on 2018-12-04: Jim Cramer Weighs In On Exelon, Okta, Wrkco And More

Financial news for IMMU dated on 2018-11-14: 13F From Omega Shows Liquidated Positions In Halcon, Humana, Int'l. Game Tech., Immunomedics, Insmmed, Iqvia, KKR, Lennar

Financial news for IMMU dated on 2018-11-07: Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer

Financial news for IMMU dated on 2018-11-07: Immunomedics, Inc. Q1 EPS \$(0.34) Misses \$(0.28) Estimate

Financial news for IMMU dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for IMMU dated on 2018-11-05: UPDATE: Morgan Stanley Earlier On New Overweight Rating For Immunomedics: Believes Approval Of IMMU-132 By Jan. 18, 2019 PDUFA Will Serve As A Robust Near-Term Catalyst

Financial news for IMMU dated on 2018-11-05: Morgan Stanley Initiates Coverage On Immunomedics with Overweight Rating, Announces \$38 Price Target

Financial news for IMMU dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for IMMU dated on 2018-10-26: The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Financial news for IMMU dated on 2018-10-19: PiperJaffray Earlier Initiated Coverage On Immunomedics with Overweight Rating, Announced \$33 Price Target

Financial news for IMMU dated on 2018-09-17: Goldman Sachs Initiates Coverage On Immunomedics with Buy Rating, Announces \$36 Price Target

Financial news for IMMU dated on 2018-09-12: UPDATE: Immunomedics Is Obligated To Pay Samsung Each Year From 2020 To 2025 Greater Of Min. Product Purchase Commitment As Set Forth In PSA

Financial news for IMMU dated on 2018-09-12: Immunomedics and Samsung BioLogics Announce Strategic Manufacturing Partnership, Partnership Involves Commercial-scale Production of hRS7, the Antibody Used in Immunomedics' Lead Antibody-Drug Conjugate, Sacituzumab Govitecan

Financial news for IMMU dated on 2018-08-24: The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict

Financial news for IMMU dated on 2018-08-23: Immunomedics 8-K Shows Michael Garone Resigned As CFO; Usama Malik Named Interim Replacement

Financial news for IMMU dated on 2018-08-23: Immunomedics Q4 EPS \$(0.68) Misses \$(0.22) Estimate, Sales \$400K Miss \$4.27M Estimate

Financial news for IMMU dated on 2018-08-23: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

Financial news for IMMU dated on 2018-08-23: Earnings Scheduled For August 23, 2018

Financial news for IMMU dated on 2018-07-30: Immunomedics Announces Clinical and Preclinical Collaborations with Yale University, Memorial Sloan Kettering Cancer Center, and Fred Hutchinson Cancer Research Center

Financial news for IMMU dated on 2018-07-23: Immunomedics Reports Clinical Partnership With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers

Financial news for IMMU dated on 2018-07-23: Immunomedics to Collaborate with AstraZeneca to Evaluate the Combination of Imfinzi and Sacituzumab Govitecan

Financial news for IMMU dated on 2018-07-18: Immunomedics Reports FDA Accepted

Biologics License Application For Filing, Grants Priority Review For Sacituzumab Govitecan For Treatment Of Metastatic Triple-negative Breast Cancer

Financial news for IMMU dated on 2018-06-13: Immunomedics Prices 11.5M Share Offering At \$24/Share

Financial news for IMMU dated on 2018-06-12: 41 Stocks Moving In Tuesday's Mid-Day Session

Financial news for IMMU dated on 2018-06-12: Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate

Financial news for IMMU dated on 2018-06-12: 26 Stocks Moving In Tuesday's Pre-Market Session

Financial news for IMMU dated on 2018-06-12: 8 Stocks To Watch For June 12, 2018

Financial news for IMMU dated on 2018-06-11: 7 Stocks Moving In Monday's After-Hours Session

Financial news for IMMU dated on 2018-06-11: UPDATE: Immunomedics Reports Offering Of \$275M In Common Stock

Financial news for IMMU dated on 2018-06-11: Immunomedics Filing Shows Registration For Mixed Securities Shelf Offering, No Amount Disclosed

Financial news for IMMU dated on 2018-06-05: Immunomedics Amended 13D Filing From Seattle Genetics Shows Reduced Stake From ~11.66M Shares To ~8.28M Shares, Or 4.9% Stake

Financial news for IMMU dated on 2018-06-05: Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

Financial news for IMMU dated on 2018-06-05: 44 Biggest Movers From Yesterday

Financial news for IMMU dated on 2018-06-04: 5 Biotech Stocks Moving On ASCO Presentations

Financial news for IMMU dated on 2018-06-04: 35 Stocks Moving In Monday's Mid-Day Session

Financial news for IMMU dated on 2018-06-04: Mid-Morning Market Update: Markets Open Higher; Palo Alto Networks Beats Q3 Estimates

Financial news for IMMU dated on 2018-06-03: Clovis Oncology, Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers

Financial news for IMMU dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for IMMU dated on 2018-06-03: Immunomedics Announces Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer at #ASCO2018

Financial news for IMMU dated on 2018-06-01: UPDATE: Immunomedics Reports Plan To Initiate Phase 2 Pivotal TROPHY U-01 Study Of Sacituzumab Govitecan As Single Agent In Patients With Locally-Advanced Or Metastatic Urothelial Cancer Who Have Relapsed After Platinum-Based Regimen

Financial news for IMMU dated on 2018-06-01: Immunomedics Reports Pivotal Study Of Sacituzumab Govitecan In Patients With Locally-Advanced Or Metastatic Urothelial Cancer

Financial news for IMMU dated on 2018-05-24: Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Financial news for IMMU dated on 2018-05-21: Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The FDA

Financial news for IMMU dated on 2018-05-18: Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Financial news for IMMU dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Financial news for IMMU dated on 2018-05-16: Immunomedics Reports Sacituzumab

Govitecan Generated Confirmed Overall Response Rate Of 31% In Heavily Pre-Treated ER+/HER2-mBC Patients, 6-Month Clinical Benefit Was 48%

Financial news for IMMU dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for IMMU dated on 2018-05-09: Immunomedics Q3 EPS \$(0.21) Misses \$(0.15) Estimate, Sales \$500K Miss \$4.27M Estimate

Financial news for IMMU dated on 2018-05-01: 36 Biggest Movers From Yesterday

Financial news for IMMU dated on 2018-04-30: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for IMMU dated on 2018-04-25: Shares Of Immunomedics Quiet As Co. Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Financial news for IMMU dated on 2018-03-28: For Now, Traders Endorse Biotech Rally

Financial news for IMMU dated on 2018-02-08: Immunomedics Reports Q2 EPS \$(0.02) vs \$(0.12) Est., Sales \$600K vs \$400K In Prior Year Period

Financial news for IMMU dated on 2018-01-11: JP Morgan Healthcare Conference Concludes Today, Presenters Include: CymaBay, Orthofix, Analogic, Achaogen, Immunomedics, and Dynavax

Financial news for IMMU dated on 2018-01-11: Immunomedics Reports Deal With University Of Wisconsin Carbone Cancer Center To Expand IMMU-132 Into Prostate Cancer

Financial news for IMMU dated on 2018-01-08: Immunomedics Earlier Announced \$250M Royalty Funding And Stock Purchase Agreement With Royalty Pharma; Co. Has Sold Rights To Sacituzumab Govitecan To Royalty Pharma For \$175M And Also Received \$75M Equity Investment, Valuing Shares At \$17.15/Share

Financial news for IMMU dated on 2018-01-08: Immunomedics Shares Halted News Pending

Financial news for IMMU dated on 2017-12-08: 32 Biggest Movers From Yesterday

Financial news for IMMU dated on 2017-12-07: Immunomedics Option Alert: Jan, 2019 \$12 Puts at the Bid: 2000 @ \$4.1 vs 243 OI; Ref=\$11.935

Financial news for IMMU dated on 2017-12-07: 31 Stocks Moving In Thursday's Mid-Day Session

Financial news for IMMU dated on 2017-12-07: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for IMMU dated on 2017-12-07: 42 Biggest Movers From Yesterday

Financial news for IMMU dated on 2017-12-06: UPDATE: Immunomedics Reports IMMU-132's Updated Clinical Benefit Rate is at 6 Months = 45% (Locally Assessed)

Financial news for IMMU dated on 2017-12-06: UPDATE: Immunomedics Announces Submission of Biologics License Application (BLA) for Accelerated Approval of Sacituzumab Govitecan as Third-Line Treatment for mTNBC Remains on Track for Q1 2018

Financial news for IMMU dated on 2017-12-06: Immunomedics Announces IMMU-132 Objective Response Rate (ORR) = 31% (Centrally Reviewed); 34% (Locally Assessed), Median Duration of Response (DOR) = 9.1 Months (Centrally Reviewed); 7.6 Months (Locally Assessed)

Financial news for IMMU dated on 2017-12-06: Immunomedics Shares Resume Trading, Up ~20% At \$10.88

Financial news for IMMU dated on 2017-12-06: Immunomedics Shares Halted On Circuit Breaker After Moving +11.4% In 10 Minutes

Financial news for IMMU dated on 2017-12-06: IMMU Option Alert: Jan, 2019 \$5 Puts Sweep (3) at the Bid: 500 @ \$1.15 vs 525 OI; Ref=\$9.1

Financial news for IMMU dated on 2017-12-05: 32 Biggest Movers From Yesterday

Financial news for IMMU dated on 2017-12-01: Jim Cramer Gives His Opinion IDT, Sherwin-Williams And Immunomedics

Financial news for IMMU dated on 2017-11-16: Immunomedics Shares Up ~20% Over Last 2 Sessions; Several Execs/Insiders Filed Form 4's Showing Purchase Of 2.8M Shares,

Including 1.325M Shares Via venBio Advisor; Stock Has Been Rangebound Between \$10 And \$12.50 Since Reporting Q1 Earnings On Nov. 9

Financial news for IMMU dated on 2017-11-16: Immunomedics 10%+ Owner venBio Select Advisor LLC Buys 1,325,000 @ Avg Price: \$10.47 -Form4

Financial news for IMMU dated on 2017-11-14: Seeing Notable Block Trade In Immunomedics of 1.3M Shares At \$10.20, Below \$10.26 Bid

Financial news for IMMU dated on 2017-11-14: 34 Biggest Movers From Yesterday

Financial news for IMMU dated on 2017-11-13: 44 Biggest Movers From Friday

Financial news for IMMU dated on 2017-11-10: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for IMMU dated on 2017-11-10: Mid-Day Market Update: Omeros Climbs After Strong Q3 Results; LightPath Technologies Shares Plunge

Financial news for IMMU dated on 2017-11-10: 31 Stocks Moving In Friday's Pre-Market Session

Financial news for IMMU dated on 2017-11-09: Immunomedics Names Michael Pehl President and CEO

Financial news for IMMU dated on 2017-11-09: Immunomedics Reports Q1 EPS \$(0.97) vs ~\$(0.17) In Same Qtr. Last Year, Sales \$700K

Financial news for IMMU dated on 2017-09-28: Watch These 10 Huge Put Purchases In Thursday Trade

Financial news for IMMU dated on 2017-09-27: Benzinga's Option Alert Recap From September 27

Financial news for IMMU dated on 2017-09-27: Immunomedics Option Alert: Jan 19 \$10 Puts Sweep (4) at the Ask: 1000 @ \$0.919 vs 96 OI; Ref=\$12.77

Financial news for IMMU dated on 2017-09-20: Immunomedics Shares Fall ~\$0.40-\$0.50 Over Last Min. As Traders Circulate Negative Report From Mako Research

Financial news for IMMU dated on 2017-09-15: Mid-Afternoon Market Update: Dow Rises Over 50 Points; T2 Biosystems Shares Plummet

Financial news for IMMU dated on 2017-09-11: PfizerImmunomedics Gives Update on Interim Phase 2 IMMU-132 Data

Financial news for IMMU dated on 2017-08-28: Mid-Afternoon Market Update: IXYS Surges On Acquisition News; Uni-Pixel Shares Plunge

Financial news for IMMU dated on 2017-08-28: Mid-Day Market Update: Crude Oil Down 2.5%; MaxPoint Interactive Shares Spike Higher

Financial news for IMMU dated on 2017-08-28: Mid-Morning Market Update: Markets Mostly Higher; Gilead Sciences To Buy Kite Pharma

Financial news for IMMU dated on 2017-08-24: Mid-Afternoon Market Update: Crude Oil Down Over 2%; Abercrombie & Fitch Shares Surge Following Strong Q2 Results

Financial news for IMMU dated on 2017-08-24: Mid-Day Market Update: Guess? Climbs After Q2 Beat; Smucker Shares Slide

Financial news for IMMU dated on 2017-08-24: Immunomedics Spikes to High of \$10.50 Following Block Trade of 435K+ Shares

Financial news for IMMU dated on 2017-08-24: Mid-Morning Market Update: Markets Edge Lower; Dollar Tree Profit Tops Expectations

Financial news for IMMU dated on 2017-08-23: Immunomedics Option Alert: Oct 20 \$10 Calls Sweep (6) at the Bid: 1000 @ \$0.517 vs 201 OI; Ref=\$9.49 Signals

Financial news for IMMU dated on 2017-08-21: Immunomedics Publishes Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate 'Promising' Efficacy

Financial news for IMMU dated on 2017-08-16: Immunomedics Reports Q4 EPS \$EPS \$(0.48) May Not Compare To \$(0.12) Est., Sales \$0.6M May Not Compare To \$2.33M Est.

Financial news for IMMU dated on 2017-08-16: Immunomedics Reiterates Guidance On BLA Submission Timeline

Financial news for IMMU dated on 2017-07-10: Immunomedics Reports Publication In 2 Cancer Journals Its Phase 2 Clinical Results With IMMU-132

Financial news for IMMU dated on 2017-07-10: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for IMMU dated on 2017-07-06: Mid-Afternoon Market Update: L Brands Falls Following Disappointing Sales Report; Herman Miller Shares Surge

Financial news for IMMU dated on 2017-07-06: Mid-Day Market Update: Crude Oil Up Over 2%; Egalet Shares Plummet

Financial news for IMMU dated on 2017-07-06: Mid-Morning Market Update: Markets Open Lower; Liberty Interactive To Acquire HSN

Financial news for IMMU dated on 2017-06-29: Companies Holding Shareholder Meetings Today Include: Allegiant Travel Co., Bed Bath & Beyond, Delek US Holdings, Gigamon, Guess, Heat Biologics, Immunomedics, Kadmon, Patterson-UTI, Tecogen, and Time Inc

Financial news for IMMU dated on 2017-06-20: Mid-Day Market Update: Crude Oil Down Over 3%; Lipocine Shares Spike Higher

Financial news for IMMU dated on 2017-06-20: Mid-Morning Market Update: Markets Open Lower; Lennar Tops Q2 Expectations

Financial news for IMMU dated on 2017-06-12: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for IMMU dated on 2017-05-31: Option Alert: Immunomedics Jun 8.0 Calls Sweep: 500 @ Above Ask! \$0.299: 1510 traded vs 4286 OI: Earnings 8/16 After Close (est) \$7.59 Ref

Financial news for IMMU dated on 2017-05-26: Benzinga's Top Upgrades, Downgrades For May 26, 2017

Financial news for IMMU dated on 2017-05-26: Cowen & Co. Initiates Coverage On Immunomedics with Outperform Rating, Announces \$15.00 Price Target

Financial news for IMMU dated on 2017-05-10: Immunomedics Reports Q3 EPS \$(0.55) vs \$(0.13) Est., Sales \$1.3M vs \$3.2M Est.

Financial news for IMMU dated on 2017-05-05: 20 Biggest Mid-Day Gainers For Friday

Financial news for IMMU dated on 2017-05-05: Mid-Day Market Update: Crude Oil Up 2%; Brightcove Shares Plummet Following Q1 Results

Financial news for IMMU dated on 2017-05-05: Mid-Morning Market Update: Markets Open Mixed; Cognizant Earnings Beat Views

Financial news for IMMU dated on 2017-05-05: UPDATE: Immunomedics Says 'Unwinding of the deal releases both companies from all material obligations subject to Court approval; Seattle Genetics maintains its existing equity stake in the Company'

Financial news for IMMU dated on 2017-05-05: Immunomedics Announces CFO Michael Garone Will Be Named Interim CEO Once Settlement Deal is Finalized

Financial news for IMMU dated on 2017-05-05: Immunomedics is Targeting BLA Submission for IMMU-132 in TNBC by Late 2017, Early 2018

Financial news for IMMU dated on 2017-05-05: Immunomedics Announces Mutual Deal with Seattle Genetics for Dissolving of Previously-Agreed Upon Exclusive Global Licensing Deal

Financial news for IMMU dated on 2017-05-05: Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan

Financial news for IMMU dated on 2017-04-05: Immunomedics Reports IMMU-132 is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy

Financial news for IMMU dated on 2017-04-04: Immunomedics Preclinical Study Shows Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan

Financial news for IMMU dated on 2017-04-04: Immunomedics Reports Sacituzumab Govitecan Has Potential To Provide Clinical Benefit To Chemosensitive Solid Tumors With Low and High Trop-2 Expression

Financial news for IMMU dated on 2017-03-23: ImmunoCellular Therapeutics and Memgen

Announce Letter of Intent for Potential Joint Immuno Oncology Collaboration

Financial news for IMMU dated on 2017-03-10: Mid-Morning Market Update: Markets Open Higher; Genesco Profit Beats Views

Financial news for IMMU dated on 2017-03-10: 8-K from Seattle Genetics Shows Delaware Court of Chancery Issued Temporary Restraining Order Enjoining Taking Any Action in Furthering of Closing of Deal between Co., Immunomedics Related to IMMU-132

Financial news for IMMU dated on 2017-03-09: Immunomedics Shares Resume, Continuing Higher, Spike to Up 13%, Now Up 10%

Financial news for IMMU dated on 2017-03-09: Immunomedics Shares Halted on Circuit Breaker, Now Up ~12%

Financial news for IMMU dated on 2017-03-09: Immunomedics Licensing Deal Over Cancer Drug Temp. Halted, Bared From Proceeding With Seattle Genetics Deal; Board Fight Over Immunomedics Spurred By Delaware Judge Ruling

Financial news for IMMU dated on 2017-03-09: Immunomedics Shares Volatile, Now Up ~3%

Financial news for IMMU dated on 2017-03-09: Immunomedics Sells off to Low of \$4.79 on Volume, tjen Reverses to High of \$5.27

Financial news for IMMU dated on 2017-03-06: Watch These 7 Huge Put Purchases In Monday Trade

Financial news for IMMU dated on 2017-03-03: Benzinga's Option Alert Recap From March 3

Financial news for IMMU dated on 2017-03-03: venBio Issues Release Highlighting Prelim. Results Indicate Immunomedics Holders Have Elected All 4 of Firm's Independent Director Nominees

Financial news for IMMU dated on 2017-03-03: Immunomedics Says Co. Will Promptly Seek RRelief In Proceeding In Delaware Chancery Court While Co.. Continues To Take Steps To Protect Rights Of All Stockholders

Financial news for IMMU dated on 2017-03-03: Option Alert: Immersion Aug 7.5 Put; 3000 @Bid @\$0.65

Financial news for IMMU dated on 2017-03-03: Immunomedics Holding Annual Shareholder Meeting Today

Financial news for IMMU dated on 2017-03-02: venBio Responds To Immunomedics PR This Morning, Calls IMMU's Comments 'Misleading', Encourages Shareholders To Vote For New Board Members

Financial news for IMMU dated on 2017-03-02: venBio Responds To Comments from Immunomedics

Financial news for IMMU dated on 2017-03-02: Immunomedics Announces Revised Settlement Offer Rejected By venBio

Financial news for IMMU dated on 2017-03-02: Traders Circulating Chatter That Immunomedics Approached For Takeover

Financial news for IMMU dated on 2017-02-27: Immunomedics Issues Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation

Financial news for IMMU dated on 2017-02-23: Immunomedics Reports Company's Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies

Financial news for IMMU dated on 2017-02-22: venBio Says It's Committed TO Delivering Much-Needed Change At Immunomedics In Shareholder Letter

Financial news for IMMU dated on 2017-02-21: Immunomedics Files Lawsuit and motion for Injunctive Relief Against venBio for Violations of Federal Securities Laws

Financial news for IMMU dated on 2017-02-17: Immunomedics Says Sacituzumab Govitecan (Immu-132) is Active In Patients With Metastatic Urothelial Cancer

Financial news for IMMU dated on 2017-02-17: Immunomedics To Launch REMAIN, An Overall Survival Study With Ceplene And Proleukin

Financial news for IMMU dated on 2017-02-15: Immunomedics Sends Letter To Stockholders Urging Them To Vote For All Seven Board Members At Upcoming Annual Mtg

Financial news for IMMU dated on 2017-02-14: Immunomedics Comments on venBio Lawsuit

Financial news for IMMU dated on 2017-02-14: Immunomedics' Shareholder venBio Select Advisor Issues Statement In Opposition To Recent Partnership With Seattle Genetics, Files Motion For Injunction

Financial news for IMMU dated on 2017-02-13: How Did Today's Zosano Pharma Short Call From Martin Shkreli Play Out?

Financial news for IMMU dated on 2017-02-13: Martin Shkreli Says He Covered Immunomedics, Comments That He Would Not Buy Zosano Pharma As A Stock Offering Is Very Likely

Financial news for IMMU dated on 2017-02-13: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for IMMU dated on 2017-02-10: venBio Comments on Immunomedics Partnership Announcement, Says Co. Blatantly Spurning Will Of Stockholders

Financial news for IMMU dated on 2017-02-10: Shkreli: I'd Short Immunomedics On The Bounce

Financial news for IMMU dated on 2017-02-10: In A Facebook Post, Martin Shkreli Says He Would Short Immunomedics On Bounce, 'I cant believe they got \$250 million for this irinotecan prodrug. The workd has moved on from old chemo mechanisma to targeted/io. That'll be the last 250 they get.'

Financial news for IMMU dated on 2017-02-10: 20 Biggest Mid-Day Gainers For Friday

Financial news for IMMU dated on 2017-02-10: Adam Feuerstein Tweets: There is some serious 3-D chess going on behind scenes w/ \$IMMU.

Financial news for IMMU dated on 2017-02-10: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for IMMU dated on 2017-02-10: Immunomedics Enters Agreement With Seattle Genetics for Exclusive Rights to Commercialize Sacituzumab Govitecan, Immunomedic to Receive \$250M Upfront, Sell \$15M of Stock to Seattle Genetics

Financial news for IMMU dated on 2017-02-09: Immunomedics Reports Q2 EPS \$(0.23) vs \$(0.13) Est, Reveneue \$0.4M vs \$3.1M Est

Financial news for IMMU dated on 2017-02-07: UPDATE: Immunomedics Says ISS, Glass Lewis 'reached wrong conclusion by over-focusing on the past'

Financial news for IMMU dated on 2017-02-07: UPDATE: Immunomedics Says venBio 'Has NO Real Plan,' Says '100-Day Plan Has NO Substance'

Financial news for IMMU dated on 2017-02-07: UPDATE: Immunomedics Says Holders Should Vote FOR Co. Director Nominees on WHITE Proxy Card

Financial news for IMMU dated on 2017-02-07: UPDATE: Immunomedics Says 'Stockholders Should Not Risk Giving venBio Directors Control of the Immunomedics Board of Directors'

Financial news for IMMU dated on 2017-02-07: Immunomedics Reports Strong Encouragement for Shareholders to Reject venBio Nominees for Co. Board

Financial news for IMMU dated on 2017-02-06: ISS Endorses Full Slate of venBio Director Nominees at Immunomedics

Financial news for IMMU dated on 2017-02-02: Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board, Deep Engagement in Robust, Value-Creating Strategic and CMC Processes

Financial news for IMMU dated on 2017-01-31: 6 Hot Stocks Among Shorts: IBM, Exxon Mobil And More

Financial news for IMMU dated on 2017-01-30: Immunomedics Urges Voters To Vote On White Proxy Card

Financial news for IMMU dated on 2017-01-26: Benzinga's Option Alert Recap From January 26

Financial news for IMMU dated on 2017-01-26: UPDATE: Immunomedics sacituzumab govitecan Data Release Last Week Has Attracted Greater Licensing Partnership Interest According To Dealreporter Contacts

Financial news for IMMU dated on 2017-01-26: Hearing Dealreporter Reporting

Immunomedics Seeing Interest From Potential Partners

Financial news for IMMU dated on 2017-01-26: Option Alert: Immunomedics Feb 6.0 Calls Sweep: 500 @ ASK \$0.25: 500 traded vs 264 OI: Earnings 2/1 After Close (est) \$4.70 Ref

Financial news for IMMU dated on 2017-01-26: Immunomedics spiking up 8.7% to a high of 4.82 on high volume

Financial news for IMMU dated on 2017-01-25: Adam Feuerstein Tweets: @chasingthealpha \$IMMU shareholder vote is Feb. 16. You can expect to see ISS recommendation about one week prior.

Financial news for IMMU dated on 2017-01-25: TheStreet's Adam Feuerstein Publishes 'Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder'

Financial news for IMMU dated on 2017-01-24: Immunomedics Mails Letter to Stockholders To Vote For All Seven Company Nominated Directors

Financial news for IMMU dated on 2017-01-18: Immunomedics Reports New Data for IMMU-132 at Investor R&D Day, Submission for Accelerated Approval Application to FDA for Patients with Metastatic TNBC Remains on Track for Mid-2017

Financial news for IMMU dated on 2017-01-09: Immunomedics Announces Antitumor Effect Of IMMU-132 Preclinical Study

Financial news for IMMU dated on 2017-01-09: Immunomedics Announces 4 New Directors, Leadership Succession Plan

Financial news for IMMU dated on 2016-12-27: Immunomedics Reports Achievement of Patient Enrollment Into Single-Arm Phase 2 Study With Sacituzumab Govitecan

Financial news for IMMU dated on 2016-12-22: Immunomedics Announces Issuance of Patent for Antibody Drug Conjugate

Financial news for IMMU dated on 2016-12-12: Immunomedics Announces Novel Immuno-Oncology Program Targeting Trop-2-Expressing Cancers

Financial news for IMMU dated on 2016-12-09: San Antonio Breast Cancer Symposium (SABCS) Continues Today, Will Conclude December 10th

Financial news for IMMU dated on 2016-12-06: Hearing M&A Chatter Suggesting Immunomedics May Be Exploring A Sale

Financial news for IMMU dated on 2016-11-29: UPDATE: venBio on Immunomedics: Believes Firm's Four Highly-Qualified Nominees Are Ideally Positioned to Effect Urgently Needed Change

Financial news for IMMU dated on 2016-11-29: venBio Issues Response Following Immunomedics' Postponing of Annual Meeting: Believes Company's Action Constitutes Unnecessary Delay and Hinders Stockholders' Ability to Voice Discontent

Financial news for IMMU dated on 2016-11-28: Mid-Morning Market Update: Markets Open Lower; Edwards Lifesciences To Buy Valtech Cardio

Financial news for IMMU dated on 2016-11-28: Immunomedics Postpones 2016 Annual Meeting of Stockholders Until February 16, 2017

Financial news for IMMU dated on 2016-11-22: Option Alert: IMMU Dec16 4.0 Calls Sweep: 775 @ ASK \$0.149: 927 traded vs 36 OI: Earnings 2/1 After Close (est) \$3.48 Ref

Financial news for IMMU dated on 2016-11-18: Watch These 7 Huge Call Purchases In Friday Trade

Financial news for IMMU dated on 2016-11-17: Option Alert: IMMU Dec16 3.0 Calls Sweep: 500 @ ASK \$0.35: 1751 traded vs 446 OI: Earnings 2/1 After Close (est) \$3.06 Ref

Financial news for IMMU dated on 2016-11-16: venBio Select Advisor Reports 9% Stake In Immunomedics 13D Filing

Financial news for IMMU dated on 2016-11-15: Immunomedics Reports Issuance of US Patent 9,492,566 Protecting Use of IMMU-132 for Treatment of Patients with Trop-2-positive Cancers

Financial news for IMMU dated on 2016-11-02: Immunomedics Reports Q1 EPS \$(0.17) vs. Est. \$(0.14), Rev. \$700K vs. Est. \$3.1M

Financial news for IMMU dated on 2016-10-24: Immunomedics Engages Greenhill & Co. as Strategic Advisor To Assist In Ongoing Efforts To Out-License sacituzumab govitecan

Financial news for IMMU dated on 2016-10-19: Immunomedics Announces Patents For Antibody Drug Conjugates, Vaccines for Cancer Therpay

Financial news for IMMU dated on 2016-10-14: Mid-Day Market Update: Advanced Micro Devices Climbs After Chip Deal With Alibaba; Ocean Power Technologies Shares Slide

Financial news for IMMU dated on 2016-10-06: Jefferies Sees Accelerated Approval Of Immunomedics' IMMU-132 'Not A Stretch'

Financial news for IMMU dated on 2016-10-06: Jefferies Assumes Immunomedics at Buy

Financial news for IMMU dated on 2016-10-05: Mid-Afternoon Market Update: Dow Gains 125 Points; Net 1 Shares Spike Higher

Financial news for IMMU dated on 2016-10-05: 12 Biggest Mid-Day Losers For Wednesday

Financial news for IMMU dated on 2016-10-05: Mid-Day Market Update: Crude Oil Up Over 2%; AZZ Shares Drop Following Q2 Results

Financial news for IMMU dated on 2016-10-05: Buyers Of Offering In Immunomedics Underwater

Financial news for IMMU dated on 2016-10-05: Mid-Morning Market Update: Markets Open Higher; Constellation Brands Tops Q2 Views

Financial news for IMMU dated on 2016-10-05: Immunomedics Reports \$30M Financing at \$3/Unit

Financial news for IMMU dated on 2016-09-19: 10 Stocks Which Rallied Three Days On Increasing Volume

Financial news for IMMU dated on 2016-08-18: 15 Biggest Mid-Day Gainers For Thursday

Financial news for IMMU dated on 2016-08-18: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for IMMU dated on 2016-08-18: Immunomedics Reports Preclinical Study on Enhancing IMMU-132 Activity in SN-38-Resistant Cancer Cells Increased Median Survival of Mice

Financial news for IMMU dated on 2016-08-17: Immunomedics Reports Q4 Loss/Share \$(0.17) vs Est Loss/Share (\$0.11), Rev \$0.9M vs \$1.2M Est

Financial news for IMMU dated on 2016-06-28: 10 Biggest Mid-Day Gainers For Tuesday

Financial news for IMMU dated on 2016-06-28: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for IMMU dated on 2016-06-28: Immunomedics Announces Patent For Sacituzumab Govitecan

Financial news for IMMU dated on 2016-06-21: Wells Fargo Downgrades Immunomedics to Market Perform

Financial news for IMMU dated on 2016-06-21: Immunomedics Names Michael R. Garone as New CFO

Financial news for IMMU dated on 2016-06-21: Immunomedics Names Michael Garone CFO

Financial news for IMMU dated on 2016-06-10: 5 Stocks Moving In Friday's After-Hours Session

Financial news for IMMU dated on 2016-06-09: Option Alert: IMMU Jun16 4.5 Puts Sweep: 500 @ ASK \$1.30: 1000 traded vs 1641 OI: \$3.29 Ref

Financial news for IMMU dated on 2016-06-06: Immunomedics Reports IMMU-132 Shows Efficacy, Safety in Non-Small Cell Lung Cancer Patients with Multiple Prior Treatments

Financial news for IMMU dated on 2016-06-06: Immunomedics Announces Sacituzumab Govitecan is Active in Patients With Previously-Treated Metastatic Small-Cell Lung Cancer, Median Progression-Free Survival Of 3.6 Months

Financial news for IMMU dated on 2016-06-03: Mid-Afternoon Market Update: Gold Rises 2.5%; Ambarella Shares Climb On Upbeat Results

Financial news for IMMU dated on 2016-06-03: Mid-Day Market Update: First Marblehead Surges Following Acquisition News; Immunomedics Shares Drop

Financial news for IMMU dated on 2016-06-03: Mid-Morning Market Update: Markets Open Lower; Broadcom Profit Beats Expectations

Financial news for IMMU dated on 2016-06-03: UPDATE: Immunomedics Says No Question was Raised on Quality of Results

Financial news for IMMU dated on 2016-06-03: Immunomedics Says Triple-Negative Breast Cancer Presentation was Cancelled Following Complaint Company Violated Embargo

Financial news for IMMU dated on 2016-06-03: 12 Stocks Moving In Friday's Pre-Market Session

Financial news for IMMU dated on 2016-06-02: Option Alert: IMMU Jan17 5.5 Calls Sweep: 742 @ ASK \$1.55: 5013 traded vs 65 OI: \$5.30 Ref

Financial news for IMMU dated on 2016-06-02: Mid-Morning Market Update: Markets Open Lower; Joy Global Profit Tops Expectations

Financial news for IMMU dated on 2016-05-23: Top 3 Pre-Market Losers Today

Financial news for IMMU dated on 2016-05-23: 12 Stocks Moving In Monday's Pre-Market Session

Financial news for IMMU dated on 2016-05-19: Option Alert: IMMU Aug16 7.0 Calls: 583 @ ASK \$0.10: 584 traded vs 6 OI: \$3.96 Ref

Financial news for IMMU dated on 2016-05-06: Jefferies Upgrades Immunomedics to Buy, Raises PT to \$5.00

Financial news for IMMU dated on 2016-05-04: Immunomedics Reports Q3 EPS \$(0.15) vs \$(0.13) Est., Sales \$900K vs \$2.13M Est.

Financial news for IMMU dated on 2016-05-02: Immunomedics Reports Abstract on IMMU-132 in Patients with Triple-Negative Breast Cancer Selected for Best of ASCO Program

Financial news for IMMU dated on 2016-04-29: Immunomedics Reports Responses With Sacituzumab Govitecan in Patients With Metastatic Solid Cancers Who Failed Prior Checkpoint-Inhibitor Therapy

Financial news for IMMU dated on 2016-04-20: Immunomedics Reports Winning of US Patent for Novel Immuno-Oncology Agents for Cancer Therapy

Financial news for IMMU dated on 2016-04-18: Immunomedics Announces Encouraging Preclinical Study Data, Shares Give Up Early Morning Gains

Financial news for IMMU dated on 2016-04-18: Immunomedics Announces Positive Results For IMMU-114 Phase 1 Trial

Financial news for IMMU dated on 2016-03-15: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for IMMU dated on 2016-03-14: 3 Stocks Witnessing Big Moves After Hours

Financial news for IMMU dated on 2016-03-14: Immunomedics Offers Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients with Advanced Pancreatic Cancer

Financial news for IMMU dated on 2016-03-08: Immunomedics Issued US Patent Related To Method Of Use Of Proprietary Anti-Histone Antibody

Financial news for IMMU dated on 2016-03-08: Immunomedics Announces Issuance of U.S. Patent for Company's New Patent Family "Methods of Treating Rapidly Progressive Glomerulonephritis Using Chimeric and Humanized Anti-Histone Antibodies"

Financial news for IMMU dated on 2016-02-09: Immunomedics Spikes to High of \$2.15 on Volume

Financial news for IMMU dated on 2016-02-03: Immunomedics Reports Q2 EPS \$(0.15) vs \$(0.14) Est., Sales \$700K vs \$1.23M Est.

Financial news for IMMU dated on 2016-01-05: Immunomedics Reports New Patent Covering the Use of Antibody-SN-38 Conjugates Combination, Company Working With FDA On Phase 3 Trial Design In Patients With Metastatic Colorectal Cancer

Financial news for IMMU dated on 2015-12-10: UPDATE: Immunomedics Reports Objective Response Rate 31%, 78% Confirmed, Median Progression-Free Survival 6 Months, 58% Maturity

Financial news for IMMU dated on 2015-12-10: Immunomedics Reports Positive Results With Sacituzumab Govitecan in Heavily Pre-Treated Metastatic Triple-Negative Breast Cancer Patients

Financial news for IMMU dated on 2015-12-07: Immunomedics Reports Initial Results of a Phase I First-In-Man Study With IMMU-114 in Hematologic Malignancies; 50% Of Patients Show Objective Evidence Of Treatment Activity

Financial news for IMMU dated on 2015-12-04: Immunomedics Shares Tumble 7+% Following Earlier Wells Fargo Downgrade

Financial news for IMMU dated on 2015-11-09: Immunomedics Reports Sacituzumab Govitecan Is Synergistic With Chemotherapeutics That Target Cell Division in Triple-Negative Breast Cancer

Financial news for IMMU dated on 2015-11-04: Immunomedics Reports Q1 EPS Loss \$0.16 Vs Est \$0.14

Financial news for IMMU dated on 2015-10-27: Immunomedics Spikes to High on Volume

Financial news for IMMU dated on 2015-10-27: Immunomedics Share Spike Higher, Up ~17.50%

Financial news for IMMU dated on 2015-10-19: Immunomedics Reports Durable Responses In Patients With Advanced Solid Cancers After Therapy With Sacituzumab

Financial news for IMMU dated on 2015-10-19: Immunomedics Reports Durable Responses in Patients With Advanced Solid Cancers After Therapy With Sacituzumab Govitecan

Financial news for IMMU dated on 2015-10-06: Option Alert: \$IMMU Oct \$1.5 Call Sweep; 2455 Contracts @Ask @ \$0.60; Now \$2.08

Financial news for IMMU dated on 2015-10-06: Immunomedics Spikes to High on Volume

Financial news for IMMU dated on 2015-09-08: Mid-Morning Market Update: Markets Open Higher; Media General To Acquire Meredith For \$2.4B

Financial news for IMMU dated on 2015-09-08: Morning Market Gainers

Financial news for IMMU dated on 2015-09-08: Benzinga's Top #PreMarket Losers

Financial news for IMMU dated on 2015-09-08: Benzinga's Top #PreMarket Gainers

Financial news for IMMU dated on 2015-09-08: Immunomedics +30% Premarket Following Announcement of Interim Phase 2 Results With Sacituzumab Govitecan in Lung Cancers

Financial news for IMMU dated on 2015-09-08: US Stock Futures Signal Higher Start On Wall Street

Financial news for IMMU dated on 2015-09-08: Immunomedics Reports Interim Phase 2 Results With Sacituzumab Govitecan in Lung Cancers

Financial news for IMMU dated on 2015-08-21: Option Alert: \$IMMU Sep \$2 Call Sweep; 1629 Contracts @Ask @\$0.25; Now \$1.95

Financial news for IMMU dated on 2015-08-19: Immunomedics Reports Inline Q2 Loss \$0.13

Financial news for IMMU dated on 2015-08-19: Immunomedics Appoints Arthur S. Kirsch as Director

Financial news for IMMU dated on 2015-08-18: Immunomedics Shares Fall to Low; May be Attributed to Seeking Alpha Post

Financial news for IMMU dated on 2015-08-18: Immunomedics Announces Additional Patent Protection For Antibody Drug Program

Financial news for IMMU dated on 2015-08-18: Immunomedics Extends U.S. Patent Protection for Antibody-Drug Conjugate Program to 2033

Financial news for IMMU dated on 2015-08-04: Immunomedics Reports Orphan Drug Designation for Veltuzumab for the Treatment of Immune Thrombocytopenia

Financial news for IMMU dated on 2015-08-02: Keep An Eye On These 6 Stocks Monday Morning

Financial news for IMMU dated on 2015-07-29: Immunomedics Downgraded At Jefferies, Firm Removes Epratuzumab Revenues From Model

Financial news for IMMU dated on 2015-07-29: Jefferies Downgrades Immunomedics to Hold, Lowers PT to \$2.00

Financial news for IMMU dated on 2015-07-28: Stocks Hitting 52-Week Lows

Financial news for IMMU dated on 2015-07-28: Morning Market Losers

Financial news for IMMU dated on 2015-07-28: Shares of Immunomedics Plunge ~46% in Pre-Market Action Following News from Co.'s Licensing Partner UCB Phase III Trial for Epratuzumab in Lupus Did Not Hit Statistically Significant Results

Financial news for IMMU dated on 2015-06-17: Option Alert: Immunomedics Jul \$7 Call; 2513 Contracts Traded vs 2088 OI; Now \$4.14

Financial news for IMMU dated on 2015-06-12: Cancer Drug Conference Gives Sector A Boost

Financial news for IMMU dated on 2015-06-05: Immunomedics Spikes Higher

Financial news for IMMU dated on 2015-06-02: Immunomedics Announces Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer

Financial news for IMMU dated on 2015-06-02: UPDATE: Immunomedics Lead Antibody-Drug Conjugate Demonstrated Mid-Stage Study Promising Anti-Tumor Activity In Lung Cancer

Financial news for IMMU dated on 2015-06-02: Immunomedics Reports Durable Responses On Metastatic Lung Cancer Patients

Financial news for IMMU dated on 2015-06-01: 16 Biotech Stocks Moving Off The ASCO Conference

Financial news for IMMU dated on 2015-06-01: Immunomedics Presents Promising Results With Sacituzumab Govitecan in Patients With Metastatic Gastrointestinal Cancers

Financial news for IMMU dated on 2015-06-01: Immunomedics Announces Complete Responses in Patients With Metastatic Triple-Negative Breast Cancer Proceeding Sacituzumab Govitecan Treatment

Financial news for IMMU dated on 2015-05-15: Immunomedics Granted Fast Track Designation By FDA For Sacituzumab Govitecan

Financial news for IMMU dated on 2015-05-12: Immunomedics Extends Patent Production In U.S. For Sacituzumab Govitecan to 2033

Financial news for IMMU dated on 2015-05-06: Immunomedics Reports Inline Q3 EPS Loss \$0.13, Sales \$1.18M Vs Est \$1.07M

Financial news for IMMU dated on 2015-05-04: Benzinga's Top #PreMarket Gainers

Financial news for IMMU dated on 2015-04-20: Shares of Immunomedics Resume Trade; Stock Now Ticker Off Session Low, at \$3.83

Financial news for IMMU dated on 2015-04-20: Shares of Immunomedics Plunge Below \$4.20 Level, Stock Now Down to \$3.72

Financial news for IMMU dated on 2015-04-20: Immunomedics Reports Patients with Advanced Breast, Lung, Esophageal, Colorectal Cancers Respond to Co.'s Novel Antibody-Direct Chemotherapy

Financial news for IMMU dated on 2015-02-19: Immunomedics Presents Updated Results Sacituzumab Govitecan In Lung Cancer

Financial news for IMMU dated on 2015-02-04: Immunomedics Reports Q2 EPS Loss \$0.12 Vs Est Loss \$0.13

Financial news for IMMU dated on 2015-01-29: Immunomedics Reports Dismissal of Putative Class Act Suit

Financial news for IMMU dated on 2015-01-20: Immunomedics Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Metastatic Gastrointestinal Cancers

Financial news for IMMU dated on 2015-01-07: Benzinga's Top Initiations

Financial news for IMMU dated on 2015-01-07: Wells Fargo Initiates Immunomedics At

Outperform

Financial news for IMMU dated on 2015-01-07: Wells Fargo Initiates Coverage on Immunomedics at Outperform

Financial news for IMMU dated on 2015-01-06: Immunomedics Names Francois Wilhelm Chief Medical Officer

Financial news for IMMU dated on 2015-01-05: Mid-Morning Market Update: Markets Open Lower; General Motors U.S. Sales Surge 19%

Financial news for IMMU dated on 2015-01-05: Morning Market Movers

Financial news for IMMU dated on 2015-01-05: Monday #PreMarket Movers: Conatus Pharmaceuticals, Brainstorm Cell Therapeutics And More

Financial news for IMMU dated on 2015-01-05: Immunomedics Reports Winning of Fast Track Designation for IMMU-132 for Triple-Negative Breast Cancer

Financial news for IMMU dated on 2014-12-17: 8-K from Immunomedics Shows Arbitrator Related to Takeda License Deal Termination Awarded No Money, All Rights to Veltuzumab Reverted Back to Co.

Financial news for IMMU dated on 2014-12-15: Immunomedics Reports Preliminary Results From Pretargeted Imaging Study in Patients With Metastatic Breast Cancer

Financial news for IMMU dated on 2014-12-12: Immunomedics Announces Expanded Phase 1/2 Trials Which Confirm Activity, Good Safety Profile of IMMU-132

Financial news for IMMU dated on 2014-12-05: Option Alert: Immunomedics May \$7 Call; 1,785 Contract Trade at Ask @\$0.35; Currently \$4.37

Financial news for IMMU dated on 2014-12-03: Immunomedics Reports Outcome of '14 Annual Meeting of Shareholders: Dr. David Goldenberg Reappointed as Chair, Brian Markison as Lead Independent Director

Financial news for IMMU dated on 2014-11-21: Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus

Financial news for IMMU dated on 2014-11-07: Immunomedics Receives Third Edison Patent Award From Research & Development Council of New Jersey

Financial news for IMMU dated on 2014-11-05: Immunomedics, Inc. Reports Q1 EPS of \$(0.13) vs \$(0.12) Est; Revenue of \$1.10M vs \$1.14M Est

Financial news for IMMU dated on 2014-10-29: UPDATE: Immunomedics Says ADC Well Tolerated At Phase 2 Dose

Financial news for IMMU dated on 2014-10-29: Immunomedics Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers

Financial news for IMMU dated on 2014-10-22: Immunomedics To Present Updated Clinical Results With Solid-Tumor Antibody-Drug Conjugates At Upcoming Conferences

Financial news for IMMU dated on 2014-10-20: Immunomedics Announces European Orphan Drug Designation for Isactuzumab Govitecan for Pancreatic Cancer Treatment

Financial news for IMMU dated on 2014-09-26: Immunomedics Publishes Results on Immunotherapy of Solid Cancers Mediated by a Novel Bispecific Antibody

Financial news for IMMU dated on 2014-09-23: Jefferies Initiates Coverage on Immunomedics, Inc. at Buy, Announces \$6.00 PT

Financial news for IMMU dated on 2014-08-25: Immunomedics, Inc. Reports Q4 EPS of \$(0.13) vs \$(0.12) Est; Revenue of \$1.19M vs \$1.20M Est

Financial news for IMMU dated on 2014-08-25: Earnings Scheduled For August 25, 2014

Financial news for IMMU dated on 2014-06-09: Immunomedics Announces Orphan Drug Designation for IMMU-132 for Pancreatic Cancer

Financial news for IMMU dated on 2014-06-01: Immunomedics Reports Development of Improved Cancer Immunotherapy at ASCO 2014

Financial news for IMMU dated on 2014-06-01: Immunomedics Reports Final Efficacy Results of Phase Ib Trial With Yttrium-90-Labeled Clivatuzumab Tetraxetan in Patients With Metastatic Pancreatic Cancer

Financial news for IMMU dated on 2014-05-20: Immunomedics Offers Results with

IMMU-132 in Patients with Pancreatic Cancer

Financial news for IMMU dated on 2014-05-19: Release from Immunomedics Shows Updated Results from 90Y-Clivatuzumab Tetraxetan, Overall Survival of 7.9 Mos. Receiving Multiple Cycles

Financial news for IMMU dated on 2014-05-13: Immunomedics Announces US Patent for IMMU-114, Will Expire May 26th, 2026

Financial news for IMMU dated on 2014-05-07: Immunomedics, Inc. Reports Q3 EPS of \$(0.11), Inline; Revenue of \$1.20M vs \$1.06M Est

Financial news for IMMU dated on 2014-05-02: Immunomedics Prices 9M Shares at \$3.35/Share

Financial news for IMMU dated on 2014-05-01: Immunomedics Announces Proposed Public Offering Of Common Stk

Financial news for IMMU dated on 2014-04-23: Immunomedics Highlights Clinical Pipeline for Solid Cancer, Lupus Therapy at R&D Day

Financial news for IMMU dated on 2014-04-09: Option Alert: ImmunoGen Apr \$14 Call; 1,700 Contracts Traded vs 80 OI; Currently \$14.53

Financial news for IMMU dated on 2014-04-07: Immunomedics Reports Multiple Partial Responses with IMMU-132 in Solid Cancers, Phase I/II Indicate Overall 77% Disease Control Rate

Financial news for IMMU dated on 2014-03-31: Immunomedics to Provide Clinical Trial on Solid-Tumor Antibody-Drug Conjugates at Cancer Conference

Financial news for IMMU dated on 2014-02-26: UPDATE: Immunomedics Extends Patnet Life to May 1st, 2032

Financial news for IMMU dated on 2014-02-26: Immunomedics Extends Patent Life on Therapeutic Antibodies

Financial news for IMMU dated on 2014-02-10: Immunomedics, Inc. Reports Q2 EPS of \$(0.10), Down 43% YOY; Revenue of \$1.20M vs \$1.20M Est

Financial news for IMMU dated on 2014-01-10: Benzinga's Top #PreMarket Gainers

Financial news for IMMU dated on 2014-01-09: UPDATE: Immunomedics Shares Rise 20% After-Hours on Initiation of Phase III Clinical Trial of Clivatuzumab Tetraxetan

Financial news for IMMU dated on 2014-01-09: Immunomedics Announces Initiation of Phase III Clinical Trial of Clivatuzumab Tetraxetan in Patients With Pancreatic Cancer

Financial news for IMMU dated on 2014-01-09: Immunomedics Reports Initiation of Phase 3 Trial of Clivatuzumab Tetraxetan, Says Primary Endpoint Will Be Overall Survival

Financial news for IMMU dated on 2013-12-31: Immunomedics Announces U.S. Patent for Antibody-SN-38 Conjugates

Financial news for IMMU dated on 2013-12-31: Immunomedics Awarded US Patent for Antibody-SN-38 Conjugates

Financial news for IMMU dated on 2013-12-09: Immunomedics Says Veltuzumab Overall Objective Response Rate 49%, Showed Activity in All Dose Levels Tested

Financial news for IMMU dated on 2013-12-04: Immunomedics Confirms Orphan Drug Designation for IMMU-132

Financial news for IMMU dated on 2013-12-03: Bloomberg Reporting Immunomedics Receives Orphan Drug Designation for Lung Cancer Treatment

Financial news for IMMU dated on 2013-11-05: Immunomedics Reports Key Patent for TROP-2 Antibody

Financial news for IMMU dated on 2013-11-04: Immunomedics, Inc. Reports Q1 EPS of \$(0.05) vs \$(0.09) Est; Revenue of \$5.50M vs \$1.42M Est

Financial news for IMMU dated on 2013-10-23: Immunomedics (IMMU) Majority-owned Subsidiary Awarded US Patent for New Vaccine Technology Targeting Dendritic Cells

Financial news for IMMU dated on 2013-10-23: Immunomedics Says 90 Y-Clivatuzumab Tetraxetan in Combo with Low-Dose Gemcitabine Active

Financial news for IMMU dated on 2013-10-22: Immunomedics Announces Multiple Objective Responses in Solid Cancers with IMMU-132, Trial Expanding to Phase 2

Financial news for IMMU dated on 2013-10-09: UPDATE: Immunomedics Announces Termination of Agreement and Return of Worldwide Rights to Veltuzumab for All Non-Cancer Indications

Financial news for IMMU dated on 2013-09-30: Immunomedics Confirms Funding Over \$1.6M from Department of Defense for Milatuzumab in Lupus

Financial news for IMMU dated on 2013-09-30: Immunomedics Says IMMU-130 Produced Partial Response in One Patient, Response Duration 4.7 Months

Financial news for IMMU dated on 2013-09-10: RF Lafferty Initiates Coverage on Immunomedics, Inc. at Buy, Announces \$8.00 PT

Financial news for IMMU dated on 2013-09-06: Benzinga's Top Pre-Market Losers

Financial news for IMMU dated on 2013-09-03: Immunomedics Announces Gorman to Retire, Names Peter Pfreundschuh as New CFO

Financial news for IMMU dated on 2013-08-14: Immunomedics Announces Update To Drug Studies

Financial news for IMMU dated on 2013-08-12: Immunomedics Advances Solid Tumor Antibody-Drug Conjugate Programs to Phase II Clinical Trials

Financial news for IMMU dated on 2013-07-16: Immunomedics Constructs New Humanized Antibody for B-Cell Mediated Cancer and Autoimmune Diseases

Financial news for IMMU dated on 2013-07-03: Immunomedics Reports First Results From Phase Ib Study of 90Y-Clivatuzumab in Patients With Metastatic Pancreatic Cancer After 2 or More Prior Therapies

Financial news for IMMU dated on 2013-06-21: Afternoon Market Gainers

Financial news for IMMU dated on 2013-06-13: Immunomedics Says UCB Offers New Results from Phase 2B Open-Label Extension Study of Epratuzumab in SLE

Financial news for IMMU dated on 2013-06-11: Immunomedics Announces Combo of 90Y-Epratuzumab-Veltuzumab is Active in Non-Hodgkin Lymphoma

Financial news for IMMU dated on 2013-06-10: 90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP

Financial news for IMMU dated on 2013-06-10: Immunomedics Announces New Novel Dual System for Tumor Detection, Imaging

Financial news for IMMU dated on 2013-05-30: Afternoon Market Gainers

Financial news for IMMU dated on 2013-05-30: Immunomedics Offers Progress of Antibody-Drug Conjugate Programs at NY Biotech Association Conference

Financial news for IMMU dated on 2013-05-08: Immunomedics, Inc. Reports Q3 EPS of \$0.11 vs \$(0.10) Est; Revenue of \$1.74M vs \$970.0K Est

Financial news for IMMU dated on 2013-05-07: Immunomedics Reports Three New Patent Wins

Financial news for IMMU dated on 2013-04-10: Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors

Financial news for IMMU dated on 2013-04-09: Immunomedics Announces First Results of Labetuzumab-SN-38 in Colorectal Cancer Study

Financial news for IMMU dated on 2013-04-01: Immunomedics Settles FINRA Arbitration Proceedings, to Receive Gross Settlement of \$18M

Financial news for IMMU dated on 2013-02-27: Immunomedics Closes Offering, Sold 7M Shares at \$2.30/Share

Financial news for IMMU dated on 2013-02-22: Stocks Hitting 52-Week Lows

Financial news for IMMU dated on 2013-02-22: Immunomedics Prices 6.09M Shares at \$2.30/Share

Financial news for IMMU dated on 2013-01-28: Algeta Initiates Research Program to Evaluate Potential of Targeted Thorium Conjugate Based on Immunomedics' Anti-Cd22

Financial news for IMMU dated on 2013-01-08: Immunomedics Announces U.S. Patent for Hexavalent DOCK-AND-LOCK Complexes

Financial news for IMMU dated on 2012-12-21: Immunomedics Wins New Patent for Antibodies Targeting CD19

Financial news for IMMU dated on 2012-12-11: Immunomedics Offers Clinical Updates on Subcutaneous Injections of Veltuzumab

Financial news for IMMU dated on 2012-12-11: Immunomedics Offers Updated Clinical Results on Potential New Treatment Regimen for NHL

Financial news for IMMU dated on 2012-12-10: Immunomedics Says Addition of Epratuzumab in Combination Chemotherapy Could Be Beneficial to Acute Lymphocytic Leukemia Patients

Financial news for IMMU dated on 2012-12-10: Immunomedics Announces Preclinical Study Showed Epratuzumab's B-Cell Modulation Effect Elucidated

Financial news for IMMU dated on 2012-11-13: Immunomedics Reports Clinically Meaningful Improvements for Lupus Patients Treated with Epratuzumab

Financial news for IMMU dated on 2012-10-11: Immunomedics Files 20M Share Securities Shelf

Financial news for IMMU dated on 2012-10-09: Immunomedics Discovers Potential New Therapy for Graft-Versus-Host Disease

Financial news for IMMU dated on 2012-10-03: Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

Financial news for IMMU dated on 2012-08-28: UPDATE: Wedbush Securities Downgrades Immunomedics to Neutral; Lacking Catalysts

Financial news for IMMU dated on 2012-08-28: Wedbush Securities Downgrades Immunomedics from Outperform to Neutral

Financial news for IMMU dated on 2012-08-23: Immunomedics Reports Q4 EPS \$-0.10 vs \$-0.09 Est; Revenues \$1M vs \$1.66M Est

Financial news for IMMU dated on 2012-06-13: Cantor Rates Immunogen New Hold, Price Target \$15

Financial news for IMMU dated on 2012-06-13: Immunomedics Reports Updated Results From Phase I Pretargeting Therapy Study in Colorectal Cancer

Financial news for IMMU dated on 2012-06-13: Immunomedics Develops Potential New Treatment Regimen for Non-Hodgkin Lymphoma

Financial news for IMMU dated on 2012-06-11: Immunomedics Reports Development of a New Labeling Kit for Attaching Fluorine-18 to Peptides and Temperature-Sensitive

Financial news for IMMU dated on 2012-06-04: Immunomedics Reports Final Survival Data From Two-Part Pancreatic Cancer Study With Yttrium-90-Labeled Clivatuzumab Tetraxetan Combined With Gemcitabine

Financial news for IMMU dated on 2012-05-11: Oppenheimer Maintains Outperform Rating, \$6 PT for Immunomedics

Financial news for IMMU dated on 2012-04-02: Immunomedics Reports Clinical Results of Pretargeted Radioimmunotherapy of Colorectal Cancer

Financial news for IMMU dated on 2012-02-08: Immunomedics Reports Q2 EPS \$0.27 vs \$(0.08) Est; Revs \$29.7M vs \$11.47M Est

Financial news for IMMU dated on 2012-01-31: Immunomedics Awarded Broad Patent for Anti-CD20 and Anti-CD22 Combination Therapy

Financial news for IMMU dated on 2012-01-20: Immunomedics Reports Final Results From Phase Ib/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan

Financial news for IMMU dated on 2012-01-18: Immunomedics Reports Clivatuzumab-Based Blood Test Highly Sensitive and Specific for Early-Stage Pancreatic Cancer Detection

Financial news for IMMU dated on 2011-12-29: Wedbush Reports Update on Immunomedics' Restructuring Plan with UCB SA

Financial news for IMMU dated on 2011-12-28: Oppenheimer Maintains Outperform on Immunomedics After Partnership Restructuring

Financial news for IMMU dated on 2011-12-28: Immunomedics and UCB Announce Restructuring of Epratuzumab License Agreement; Immunomedics Will Receive \$30M

Financial news for IMMU dated on 2011-12-14: Immunomedics Awarded New Patent for Improved Cell Lines for Protein Therapeutic Manufacturing

Financial news for IMMU dated on 2011-12-14: Immunomedics Awarded New Patent for Improved Cell Lines for Protein Therapeutic Manufacturing

Financial news for IMMU dated on 2011-12-13: Notable Call Options Activity in Immunomedics

Financial news for IMMU dated on 2011-12-13: Immunomedics Announces Results From Two Clinical Trials at Hematology Conference

Financial news for IMMU dated on 2011-12-13: Immunomedics Develops Novel Antibody-Based Therapeutics for Mantle Cell and Other Lymphomas

Financial news for IMMU dated on 2011-12-12: Immunomedics Reports Subcutaneous Injections of Low-Dose Veltuzumab Produced High Rates of Response in Relapsed Immune

Financial news for IMMU dated on 2011-11-15: Immunomedics Awarded Additional U.S. Patent for Anti-CD20 Treatment of Autoimmune Diseases

Financial news for IMMU dated on 2011-11-11: Immunomedics Receives Thomas Alva Edison Patent Award From Research & Development Council of New Jersey

Financial news for IMMU dated on 2011-11-08: Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint

Financial news for IMMU dated on 2011-11-02: Immunomedics Announces FDA Allows Resumption of Clivatuzumab Tetraxetan Clinical Trial

Financial news for IMMU dated on 2011-10-11: End-of-Day Market Summary for October 11, 2011

Financial news for IMMU dated on 2011-10-11: Immunomedics Awarded U.S. Patent for Cytokine-Antibody Complexes

Financial news for IMMU dated on 2011-09-23: Oppenheimer Outperform on Immunomedics

Financial news for IMMU dated on 2011-09-22: Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical Trial

Financial news for IMMU dated on 2011-08-24: Immunomedics Reports Q4 Prelim EPS \$0.03 vs \$(0.06) Est; Revenues \$11.1M vs \$3.43M Est

Financial news for IMMU dated on 2011-06-27: Immunomedics Receives Third Milestone Payment From Nycomed of \$10M

Financial news for IMMU dated on 2011-06-08: Immunomedics Reports Advances With New Imaging Agent Developments for Positron Emission Tomography

Financial news for IMMU dated on 2011-06-07: Immunomedics Announces Antibody-Directed Radiation Therapy Appears to Improve Response to Standard-of-Care for Aggressive Lymphoma

Financial news for IMMU dated on 2011-06-07: Immunomedics Reports Final Survival Data With Yttrium-90-Labeled Clivatuzumab Tetraxetan and Low-Dose Gemcitabine in Advanced Pancreatic Cancer

Financial news for IMMU dated on 2011-06-06: Immunomedics Reports First Clinical Results of New Antibody-Directed Radiation Therapy for Colorectal Cancer

Financial news for IMMU dated on 2011-05-10: Immunomedics Reports Q3 EPS of \$(0.10) vs \$(0.08) Estimate (IMMU)

Financial news for IMMU dated on 2011-05-02: Immunomedics Announces Results From Single-Dose Escalation Study of Y-90-Clivatuzumab Tetraxetan in Advanced Pancreatic Cancer Published

Financial news for IMMU dated on 2011-04-06: Unconfirmed Rumors Circulate that (GSK) will acquire (IMMU) at 10.00 a share

Financial news for IMMU dated on 2011-04-06: Unconfirmed Rumors Circulate that (GSK) will acquire (IMMU) at 10.00 a share

Financial news for IMMU dated on 2011-04-05: Immunomedics Reports Progress on

Development of Antibody-SN-38 Conjugates at Cancer Meeting

Financial news for IMMU dated on 2011-03-24: Immunomedics Awarded Three US Patents Covering Its Cancer Therapeutic Product Candidates and Technologies

Financial news for IMMU dated on 2011-01-21: Calls Purchased on Immunomedics, Inc. (IMMU)

Financial news for IMMU dated on 2011-01-21: Could This Company Help Steve Jobs? (IMMU, AAPL)

Financial news for IMMU dated on 2011-01-12: UCB's Progress On-Track - Analyst Blog

Financial news for IMMU dated on 2011-01-12: UCB's Progress On-Track - Analyst Blog

Financial news for IMMU dated on 2010-12-15: UCB Commences Patient Enrolment - Analyst Blog

Financial news for IMMU dated on 2010-12-15: UCB Commences Patient Enrolment - Analyst Blog

Financial news for IMMU dated on 2010-11-05: Zacks' Voice of the People highlights opportunities with Immunomedics, Coca-Cola Amatil, Wyndham Worldwide, Krispy Kreme and TPC Group - Press Releases

Financial news for IMMU dated on 2010-11-04: Is Zacks Really Any Good? - Voice of the People

Financial news for IMMU dated on 2010-10-21: Unconfirmed rumor that GlaxoSmithKline plc (GSK) will acquire Immunomedics Inc. (IMMU) at \$12.00

Financial news for IMMU dated on 2010-06-16: Early Volume Plays Among Those Valued Below \$10 (HEV, SNV, SBIB, IMMU, PWER)

Financial news for IMMU dated on 2010-06-16: Benzinga's Top Pre-Market Gainers (SMTS, NBIX, IMMU, CLNE)

Financial news for IMMU dated on 2010-05-11: Brean Murray Carret & Co. Sees Huge Upside In Immunomedics (IMMU)

Financial news for IMMU dated on 2010-04-19: Benzinga's Top Pre-Market Gainers (IMMU, POZN, ONXX, TASR, SQNM)

Financial news for IMMU dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for IMMU dated on 2010-02-23: Benzinga's Top Pre-Market Gainers (HD, M, IMMU, TXIC, FDML)

Financial news for IMMU dated on 2010-02-17: Benzinga's Intraday Sector Leaders

Financial news for IMMU dated on 2010-01-25: Immunomedics, Inc. (NASDAQ: IMMU) Climbs On News

Financial news for IMMU dated on 2010-01-22: Benzinga's Top Pre-Market Gainers (ANDS, LOGI, IMMU, CNXT, APWR, ERIC)

Financial news for IMMU dated on 2010-01-11: Benzinga's Top Pre-Market Gainers (DDSS, IMMU, VVUS, LUNA, AA, SOLF, TUES)